View Filing Data

Print Document View Excel Document

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2020
Document and Entity Information
Entity Registrant Name	Centogene N.V.
Entity Central Index Key	0001757097
Document Type	6-K
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1

Interim condensed consolidated statements of comprehensive loss - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Interim condensed consolidated statements of comprehensive loss
Revenue	€ 12,105	€ 10,715
Cost of sales	7,018	6,744
Gross profit	5,087	3,971
Research and development expenses	2,691	1,701
General administrative expenses	7,898	5,910
Selling expenses	2,326	2,011
Other operating income	945	1,098
Other operating expenses	1,275	342
Operating loss	(8,158)	(4,895)
Interest and similar income		8
Interest and similar expense	449	220
Financial costs, net	(449)	(212)
Loss before taxes	(8,607)	(5,107)
Income tax expenses	129	174
Loss for the period	(8,736)	(5,281)
Other comprehensive income, all attributable to equity holders of the parent	76	2
Total comprehensive loss	(8,660)	(5,279)
Attributable to:
Equity holders of the parent	(8,599)	(5,210)
Non-controlling interests	(61)	(69)
Total comprehensive loss	€ (8,660)	€ (5,279)
Loss per share-Basic and diluted	€ (0.43)	€ (0.33)

Interim condensed consolidated statements of financial position - EUR (€) € in Thousands	Mar. 31, 2020	Dec. 31, 2019
Non-current assets
Intangible assets	€ 14,518	€ 14,145
Property, plant and equipment	8,709	8,376
Right-of-use assets	24,710	24,932
Other assets	2,098	1,948
Non-current assets	50,035	49,401
Current assets
Inventories	5,849	1,809
Trade receivables	14,646	16,593
Other assets	8,890	8,612
Cash and cash equivalents	33,381	41,095
Current assets	62,766	68,109
Total assets	112,801	117,510
Equity
Issued capital	2,383	2,383
Capital reserve	99,156	98,099
Retained earnings and other reserves	(49,221)	(40,622)
Non-controlling interest	(731)	(938)
Equity	51,587	58,922
Non-current liabilities
Non-current loans	768	1,578
Lease liabilities	18,826	18,069
Deferred tax liabilities	121
Government grants	9,773	9,941
Non-current liabilities	29,488	29,588
Current liabilities
Government grants	1,364	1,348
Current loans	3,852	3,688
Lease liabilities	3,625	3,635
Trade payables	10,173	8,554
Other liabilities	12,712	11,775
Current liabilities	31,726	29,000
Equity and liabilities	€ 112,801	€ 117,510

Interim condensed consolidated statements of cash flows - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Loss before taxes	€ (8,607)	€ (5,107)
Adjustments to reconcile earnings to cash flow from operating activities
Amortization and depreciation	2,084	1,397
Interest income		(8)
Interest expense	449	220
Expected credit loss allowances on trade receivables	1,174	340
Sharebased payment expenses	1,057	2,633
Other non-cash items	(192)	(268)
Changes in operating assets and liabilities:
Inventories	(4,040)	(275)
Trade receivables	773	(2,073)
Other assets	(234)	(967)
Trade payables	1,619	507
Other liabilities	1,751	328
Cash flow used in operating activities	(4,166)	(3,273)
Investing activities
Cash paid for investments in intangible assets	(1,191)	(1,113)
Cash paid for investments in property, plant and equipment	(644)	(441)
Grants received for investment in property, plant and equipment	207	0
Interest received		8
Cash flow used in investing activities	(1,628)	(1,546)
Financing activities
Cash received from loans	414	1,864
Cash repayments of loans	(1,060)	(451)
Cash repayments of lease liabilities	(1,044)	(461)
Interest paid	(230)	(220)
Cash flow generated from/(used in) financing activities	(1,920)	732
Changes in cash and cash equivalents	(7,714)	(4,087)
Cash and cash equivalents at the beginning of the period	41,095	9,222
Cash and cash equivalents at the end of the period	€ 33,381	€ 5,135

Interim condensed consolidated statements of changes in equity - EUR (€) € in Thousands	Total	Issued capital	Capital reserve	Currency translation reserve	Retained earnings	Non-controlling interests	Total
Balance at beginning of the period at Dec. 31, 2018	€ 27,281	€ 1,903	€ 45,342	€ (16)	€ (19,948)	€ (757)	€ 26,524
Loss for the period	(5,212)				(5,212)	(69)	(5,281)
Other comprehensive loss	2			2			2
Total comprehensive loss	(5,210)			2	(5,212)	(69)	(5,279)
Share-based payments	181		181				181
Balance at end of the period at Mar. 31, 2019	22,252	1,903	45,523	(14)	(25,160)	(826)	21,426
Balance at beginning of the period at Dec. 31, 2019	59,860	2,383	98,099		(40,622)	(938)	58,922
Loss for the period	(8,675)				(8,675)	(61)	(8,736)
Other comprehensive loss	76			76			76
Total comprehensive loss	(8,599)			76	(8,675)	(61)	(8,660)
Share-based payments	1,057		1,057				1,057
Disposal of non-wholly owned subsidiary						268	268
Balance at end of the period at Mar. 31, 2020	€ 52,318	€ 2,383	€ 99,156	€ 76	€ (49,297)	€ (731)	€ 51,587

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2019-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2019-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2019-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2019-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2019-03-27

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2019-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2019-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2019-03-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23&doctype=Standard
-URIDate 2019-03-27

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2019-03-27

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2019-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2019-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2019-03-27

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2019-03-27

+ Details

General company information	3 Months Ended
General company information	Mar. 31, 2020
General company information
General company information	1 General company information Centogene N.V. (“the Company”) and its subsidiaries focus on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The mission of the Company is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. On November 7, 2019, the Company completed an initial public offering (“IPO”) and is listed on Nasdaq Global Market under stock code “CNTG”. 4 million common shares with a nominal value of EUR 0.12 per share were sold at a public offering price of USD 14 per share (i.e. EUR 12.58 per share), for aggregate net offering proceeds, after deducting underwriting discounts and commissions, of EUR 47 million. In connection with the IPO, common shares and preference shares of Centogene AG, the previous parent holding company of the Group and the principal operating subsidiary were exchanged to common shares of Centogene B.V., and Centogene B.V. changed its legal form and became Centogene N.V. and common shares of Centogene B.V. were converted to common shares of Centogene N.V. As a result, Centogene N.V. became the holding company with 100% interest in Centogene AG since November 12, 2019. Centogene N.V. is a public company with limited liabilities incorporated in the Netherlands, with registered office located at Am Strande 7 in 18055 Rostock, Germany and trade register number 72822872.

Basis of preparation	3 Months Ended
Basis of preparation	Mar. 31, 2020
Basis of preparation
Basis of preparation	2 Basis of preparation The interim condensed consolidated financial statements for the three months ended March 31, 2019 and 2020 have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2018 and 2019 and for the three years ended December 31, 2019. The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2019, except for the adoption of new standards effective as of January 1, 2020 (see note 3). The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Several other amendments and interpretations apply for the first time in 2020, but do not have an impact on the interim condensed consolidated financial statements of the Group. These interim condensed consolidated financial statements are presented in euro, which is the Group's functional currency. Unless otherwise specified, all financial information presented in euro is rounded to the nearest thousand (EUR k) in line with customary commercial practice.

Effects of new accounting standards

3 Months Ended

Mar. 31, 2020

Effects of new accounting standards

Effects of new accounting standards

3 Effects of new accounting standards

Amendments to IAS 1 and IAS 8: Definition of Material

The amendments provide a new definition of material that states “information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity.”

The amendments clarify that materiality will depend on the nature or magnitude of information, either individually or in combination with other information, in the context of the financial statements. A misstatement of information is material if it could reasonably be expected to influence decisions made by the primary users.

These amendments had no impact on the consolidated financial statements of, nor is there expected to be any future impact to the Group since the amendment mainly clarifies the definition.

Other new accounting standards

In addition to Amendments to IAS 1 and IAS 8: Definition of Material, the following other amendments and interpretations also apply for the first time in 2020:

Amendments to IFRS 3: Definition of a Business

Amendments to IFRS 7, IFRS 9 and IAS 39: Interest Rate Benchmark Reform

References to the Conceptual Framework for Financial Reporting issued on 29 March 2018

These amendments and new standards had no impact on the consolidated financial statements of the Group.

Revenues from contracts with customers

3 Months Ended

Mar. 31, 2020

Revenues from contracts with customers

Revenues from contracts with customers

4 Revenues from contracts with customers


in EUR k	Three months ended March 31, 2019
	Pharmaceutical	Diagnostics	Total
Rendering of services	3,806	6,585	10,391
Sales of goods	324	—	324
Total Revenues from contracts with external customers	4,130	6,585	10,715

Recognized over time	3,456	6,585	10,041
Recognized at a point in time	674	—	674
Total Revenues from contracts with external customers	4,130	6,585	10,715

Geographical information
Europe	2	1,528	1,530
—Germany*	—	62	62
Middle East	—	3,522	3,522
—Saudi Arabia#	—	1,687	1,687
North America	4,128	677	4,805
—United States#	4,128	408	4,536
Latin America	—	638	638
Asia Pacific	—	220	220
Total Revenues from contracts with external customers	4,130	6,585	10,715

* country of the incorporation of Centogene AG

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended March 31, 2019


in EUR k	Three months ended March 31, 2020
	Pharmaceutical	Diagnostics	Total
Rendering of services	4,274	7,555	11,829
Sales of goods	276	—	276
Total Revenues from contracts with external customers	4,550	7,555	12,105

Recognized over time	4,274	7,555	11,829
Recognized at a point in time	276	—	276
Total Revenues from contracts with external customers	4,550	7,555	12,105

Geographical information
Europe	44	1,617	1,661
—Germany*	19	73	92
—Netherlands**	—	3	3
Middle East	3	4,415	4,418
—Saudi Arabia#	—	3,033	3,033
North America	4,503	620	5,123
—United States#	4,503	471	4,974
Latin America	—	746	746
Asia Pacific	—	157	157
Total Revenues from contracts with external customers	4,550	7,555	12,105

* country of the incorporation of Centogene AG

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended March 31, 2020

We collaborated with the majority of our pharmaceutical partners on a worldwide basis in 2019 and 2020. In addition, in cases where our pharmaceutical partners are developing a new rare disease treatment, it is generally anticipated that the final approved treatment will be made available globally. As a result, we allocate the revenues of our pharmaceutical segment by geographical region by reference to the location where each pharmaceutical partner mainly operates, which is based on the region from which most of their revenues are generated. The allocation of revenues in our diagnostics segment is based on the location of each customer.

During the three months ended March 31, 2020, revenues from one pharmaceutical partner represented 26.4% of the Group's total revenues (the three months ended March 31, 2019: 27.4%).

During the three months ended March 31, 2019, we have entered into a collaboration with an existing pharmaceutical partner, of which upfront fees totaling EUR 350k, representing the transaction price allocated to the one-off transfer of the Group's intellectual property, were received and recognized as revenues. No such revenues were recognized in the three months ended March 31, 2020.

The Group recognized impairment losses on receivables and contract assets arising from contracts with customers, included under Other operating expenses in the consolidated statement of comprehensive loss, amounting to EUR 1,174k for the three months ended March 31, 2020 (for the three months ended March 31, 2019: EUR 340k).

Segment information

3 Months Ended

Mar. 31, 2020

Segment information

Segment information

5 Segment information


	Three months ended March 31, 2019
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	4,130	6,585	—	10,715

Adjusted EBITDA	2,944	11	(3,820)	(865)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	7	20	414	441
Additions to intangible assets	768	—	345	1,113

Other segment information
Depreciation and amortization	256	524	617	1,397
Research and development expenses	—	—	1,701	1,701


	Three months ended March 31, 2020
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	4,550	7,555	—	12,105

Adjusted EBITDA	2,608	87	(7,712)	(5,017)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	—	817	587	1,404
Additions to intangible assets	1,002	—	189	1,191

Other segment information
Depreciation and amortization	564	544	976	2,084
Research and development expenses	—	—	2,691	2,691

Adjustments

Corporate expenses, depreciation and amortization, interest and similar income and expenses, as well as share-based payment expenses are not allocated to individual segments as the underlying instruments are managed on a group basis. Current taxes and deferred taxes are allocated to Corporate as they are also managed on a group basis.

Increases in corporate expenses for the three months ended March 31, 2020 are mainly due to our continued international growth and business expansion. The increase is also due to the costs of operating as a public company, such as additional legal, accounting, corporate governance and investor relations expenses, and higher directors' and officers' insurance premiums. Corporate expenses for the three months ended March 31, 2019 also included expenses incurred in relation to the IPO as described in note 1 of EUR 109k (included in General Administrative Expenses). No such expenses incurred in the three months ended March 31, 2020.

Capital expenditure consists of additions of property, plant and equipment, right-of-use assets and intangible assets. All of such assets are located in Germany, which is the country of the registered office of the Company, except for property, plant and equipment of EUR 276k (December 31, 2019: EUR 286k) and right-of-use assets of EUR 960k (December 31, 2019: EUR 1,042k), which is located in the United States.

Reconciliation of segment Adjusted EBITDA to Group loss for the period


For the three months ended March 31	2019	2020
Reported segment Adjusted EBITDA	2,955	2,695
Corporate expenses	(3,820)	(7,712)
	(865)	(5,017)
Share-based payment expenses	(2,633)	(1,057)
Depreciation and amortization	(1,397)	(2,084)
Operating loss	(4,895)	(8,158)
Financial costs, net	(212)	(449)
Income tax expenses	(174)	(129)
Loss for the three months ended March 31	(5,281)	(8,736)

Other income and expenses

3 Months Ended

Mar. 31, 2020

Other income and expenses

Other income and expenses

6 Other income and expenses

6.1Other operating income


	For the three months ended March 31
in EUR k	2019	2020
Government grants	967	702
Income from the reversal of provisions	89	—
Others	42	243
Total other operating income	1,098	945

Government grants contain performance-based grants to subsidize research, development and innovation in the state of Mecklenburg-Western Pomerania from funds granted by the European Regional Development Fund. Furthermore, government grants contain the release of deferred income from investment related grants.

6.2Other operating expenses


	For the three months ended March 31
in EUR k	2019	2020
Currency losses	2	—
Expected credit loss allowances on trade receivables	340	1,174
Others	—	101
Total other operating expenses	342	1,275

Considering the impact of COVID-19 pandemic to the global economy and the unforeseeable potential magnitude of the ultimate disruptions to different businesses, the Group has taken such into consideration when assessing the credit risk, in particular regarding the MENA region for the diagnostic segment as it represents the majority of that segment's revenue. Such assessment resulted in additional credit loss of EUR 1,174k for the three months ended March 31, 2020 (the three months ended March 31, 2019: EUR 340k). See also note 7.

During the three months ended March 31, 2020, the Group disposed of its entire 51% interest in LPC GmbH (“LPC”) to the minority shareholders at a consideration of EUR 213k, among which EUR 200k is to be paid over a period of four years (and included in other assets, see note 7). The related non-controlling interest of EUR 268k (accumulated share of loss) were debited to profit or loss and the sale resulted in a loss of EUR 101k.

Trade and other receivables and other assets

3 Months Ended

Mar. 31, 2020

Trade and other receivables and other assets

Trade and other receivables and other assets

7 Trade and other receivables and other assets


in EUR k	Dec 31, 2019	Mar 31, 2020
Non‑current
Other assets - Rental deposits	1,948	1,948
Other assets – Others	—	150
	1,948	2,098
Current
Trade receivables	12,709	11,089
Contract assets	3,884	3,557
Receivables due from shareholders	2,766	2,766
Other assets	5,846	6,124
	25,205	23,536
Total non-current and current trade and other receivables and other assets	27,153	25,634

Trade receivables and contract assets

Trade receivables are non-interest bearing and are generally due in 30 to 90 days. In general, portfolio-based expected credit loss allowances are recognized on trade receivables and contract assets.

Considering the potential impact of COVID-19 to the economy, the Group has re-assessed the credit loss rates in relation to the outstanding trade receivables and contract assets as follows:


in EUR k	Dec 31, 2019		Mar 31, 2020
Not past due	11,102		9,725
Past due 1-30 days	1,113		1,084
Past due 31-90 days	1,708		2,031
Past due more than 90 days	5,005		5,315
Total Gross amount of trade receivables and contract assets	18,928		18,155

Expected credit loss rate
Not past due	0.3	%	0.3	%
Past due 1-30 days	1.0	%	1.3	%
Past due 31-90 days	1.2	%	1.6	%
Past due more than 90 days	45.4	%	64.7	%
Expected credit loss rate on total gross trade receivables and contract assets	12.3	%	19.3	%

Expected credit loss	2,335		3,509

Receivables due from shareholders

In 2016, the Group established a virtual share option program ("2016 VSOP") under Centogene AG that entitles the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. Upon the completion of IPO in November 2019, all options granted under the option program were vested immediately in full, and the holders of vested options are entitled to receive a direct cash payment from the Company according to the calculation as stipulated in the program, which is determined based on the IPO price of the shares of Centogene N.V. and the exercise prices of the vested options.

The payable by the Group to the holders of vested options was recorded as a liability with a carrying amount of EUR 2,766k (December 31, 2019: EUR 2,766k) (see note 10.2).

As the payment to the option holders will be reimbursed by the original shareholders to the Company, a respective receivable against shareholders was recorded. Such receivables were considered as additional capital from shareholders and recorded against equity (capital reserve).

Other assets

The non-current portion of other assets include cash deposit of EUR 1,500k (used to secure a bank guarantee of EUR 3,000k) relating to the leases of Rostock headquarters building, rental deposits of EUR 257k relating to the leases of Berlin offices and EUR 191k for the leases of certain plant and machineries. It also includes the consideration receivable for the sale of LPC of EUR 213k, among which EUR 150k is due after 1 year (see note 6.2).

The current portion of other assets also include VAT receivables of EUR 1,744k (December 31, 2019: EUR 1,311k), prepaid expenses of EUR 2,834k (December 31, 2019: EUR 3,481k) as well as receivables from grants of EUR 743k (December 31, 2019: EUR 409k).

Cash and short-term deposits	3 Months Ended
Cash and short-term deposits	Mar. 31, 2020
Cash and short-term deposits
Cash and short term deposits	8 Cash and short‑term deposits As of March 31, 2020, the Group has pledged its short-term deposits with carrying amount of EUR 1,500k (December 31, 2019: EUR 1,500k) and EUR 2,500k (December 31, 2019: EUR 2,500k) respectively, to fulfil collateral requirements in respect of existing secured bank loan and overdraft facility up to EUR 2,500k. In addition, the Group has pledged its short-term deposits of EUR 500k (December 31, 2019: EUR nil) related to another overdraft facility up to EUR 500k. The restriction applying to the collateral may be terminated at any time subject to the full amount of the relevant bank loans and the overdrafts being repaid.

Equity	3 Months Ended
Equity	Mar. 31, 2020
Equity [Abstract]
Equity	9 Equity As discussed in note 1, Centogene N.V. became the parent holding company of the Group on November 12, 2019 as part of the IPO process. All share, per-share and related information presented in the financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share split resulting from the reorganization. Capital reserve As of March 31, 2020, capital reserve included a share premium of EUR 90,297k, being amounts contributed by shareholders at the issuance of shares in excess of the par value of the shares issued, net of any transaction costs incurred for the share issuance. In addition, it also included amounts recorded in respect of share-based payments. For additional information on the share-based payments, see note 11.

Financial liabilities

3 Months Ended

Mar. 31, 2020

Financial liabilities

Financial liabilities

10 Financial liabilities

10.1Interest-bearing liabilities


in EUR k	Dec 31, 2019	Mar 31, 2020
Non‑current liabilities
Non‑current portion of secured bank loans	968	768
Municipal loans	610	—
Total non‑current loans	1,578	768
Lease liabilities	18,069	18,826
Total non‑current liabilities	19,647	19,594

Current liabilities
Current portion of secured bank loans	802	802
Bank overdrafts	2,636	3,050
Municipal loans	250	—
Total current loans	3,688	3,852
Current portion of lease liabilities	3,635	3,625
Total current liabilities	7,323	7,477
Total non‑current and current liabilities	26,970	27,071

As of March 31, 2020, short-term cash deposits of EUR 1,500k (December 31, 2019: EUR 1,500k) were used to secure the secured bank loan outstanding (see note 8).

The following table is based on the original terms and conditions:

Conditions and statement of liabilities

The outstanding interest-bearing liabilities as of March 31, 2020 and December 31, 2019 have the following conditions:


					Dec 31, 2019		Mar 31, 2020
		Nominal			Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	interest rate		Maturity	amount	amount	amount	amount
Secured bank loan	EUR	3.95	%	2018‑25	1,770	1,770	1,570	1,570
Municipal loan	EUR	8.25%; plus 1.5% profit-related; 0.75% on losses		2018-23	500	500	—	—
Municipal loan	EUR	8%; plus 1.5% profit-related; 0.75% on losses		2021	360	360	—	—
Bank overdrafts	EUR	4.46	%	2022	476	476	476	476
Bank overdrafts	EUR	3.75	%	Rollover	2,160	2,160	2,094	2,094
Bank overdrafts	EUR	3.59	%	Rollover	—	—	480	480
Lease liabilities	EUR	3.5%*, 5. 4%-8.9%		2017-31	21,704	21,704	22,451	22,451
Total interest‑bearing financial liabilities					26,970	26,970	27,071	27,071

* represents the incremental borrowing rate of the Group at the commencement of the leases

The bank overdrafts of EUR 2,094k as of March 31, 2020 (December 31, 2019: EUR 2,160k) were secured by short-term deposits with a carrying amount of EUR 2,500k (December 31, 2019: EUR 2,500k) (see note 8). The bank overdrafts of EUR 476k (December 31, 2019: EUR 476k) were secured by guarantees provided by certain of the Company's shareholders as of December 31, 2019, and were released providing security over a short-term deposit with a carrying amount of EUR 500k subsequent to the year end (see note 8).

The municipal loan due to MBMV (Mittelständische Bürgschaftsbank Mecklenburg-Vorpommern) of EUR 860k outstanding as of December 31, 2019 was secured by guarantees provided by the Group's shareholders, and were released upon full repayment in February 2020.

10.2Trade payables and other liabilities


in EUR k	Dec 31, 2019	Mar 31, 2020
Trade payables	8,554	10,173
Government grants (deferred income)	11,289	11,137
Liability for Virtual Stock Option Program	2,769	2,766
Contract liabilities	3,748	3,523
Others	5,258	6,423
Trade payables and other liabilities	31,618	34,022
Non‑current	9,941	9,773
Current	21,677	24,249

Government grants mainly include investment-related government grants. These were received for the purchase of certain items of property, plant and equipment for the research and development facilities in Mecklenburg-Western Pomerania, including the Rostock facility. The grants were issued in the form of investment subsidies as part of the joint federal and state program, "Verbesserung der regionalen Wirtschaftsstruktur" (improvement of the regional economic structure) in connection with funds from the European Regional Development Fund. Additional grants received during the three months ended March 31, 2020 are related to the purchase of certain items of property, plant and equipment amounted to EUR 207k (the three months ended March 31, 2019: EUR nil).

In addition, other liabilities include personnel-related liabilities for vacation and bonuses totaling EUR 2,734k (December 31, 2019: EUR 2,264k) as well as liabilities for wage and church tax of EUR 356k (December 31, 2019: EUR 376k). Other liabilities as of December 31, 2019 also include costs relating to IPO of EUR 565k.

Share-based payments	3 Months Ended
Share-based payments	Mar. 31, 2020
Share-based payments
Share-based payments	11 Share‑based payments At March 31, 2020 the Group had the following share‑based payment arrangements. (i) Equity share option - Replacement (ESOP 2017) In 2017, the Group established a second virtual share option program ("2017 VSOP”) that entitled the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. In connection with the IPO (see note 1), a transfer agreement was entered into between the holders of the 2017 VSOP, Centogene AG and the Company in November 2019, under which the 2017 VSOP was terminated, and the option holders were granted new share options of the Centogene N.V. (“ESOP 2017”). The number of options granted to each holder under ESOP 2017 was based on the number of options granted to them under 2017 VSOP and the IPO price of Centogene N.V. Accordingly, 805,308 new share options were granted pursuant to the Centogene N.V. Long-term Incentive Plan, with each option representing one common share of Centogene N.V., and an exercise price equal to the nominal value of the share of Centogene N.V., which is EUR 0.12. The options were considered vested upon the completion of the IPO, but are not exercisable in the first 180 days subsequent to the listing (lock-up period). The contractual life for the share options as at March 31, 2020 is 9.7 years (December 31, 2019: 10 years). The fair value of share options issued under ESOP 2017 are equity-settled and the fair value of the options were fully recognized in equity under capital reserve on the date of grant. (ii) Equity share option 2019 (ESOP 2019) In 2019, an agreement was entered into between the Company and an individual of the Supervisory Board. According to this agreement, a total of 396,522 options, each option representing one common share, were granted pursuant to the Centogene N.V. Long-term Incentive Plan to the individual Supervisory Board member with exercise price equaling to the IPO price, which is EUR 12.58 per option, on the date of the IPO of the Company. The vesting period shall be three years commencing on the day of grant, where one-third of the granted options shall be vested at the end of each year of grant, and the first year ending on March 31, 2020. The contractual life for the share options as at December 31, 2019 is ten years and the weighted average fair value of options outstanding was EUR 9.08. The share options issued under “ESOP 2019” will be equity-settled and the fair value of the options were recognized in equity under capital reserve, based on the fair value on the date of grant, and will be charged to profit or loss over the vesting period. For the three months ended March 31, 2020, the Group recognized EUR 1,057k of share-based payment expense in the statement of comprehensive income. For the three months ended March 31, 2019, the Group recognized EUR 2,633k of share-based payment expense in the statement of comprehensive income in relation to the cash-settled virtual share option programs of Centogene AG, which were cancelled upon completion of IPO.

Commitments	3 Months Ended
Commitments	Mar. 31, 2020
Commitments
Commitments	12 Commitments Future payments for non-cancellable leases The Group has various lease contracts in relation to expansion of Rostock headquarters and leasing of Hamburg laboratory that have not yet commenced as at March 31, 2020. The future lease payments and utilities for these non-cancellable lease contracts are EUR 103k within one year, EUR 1,669k within five years and EUR 5,324k thereafter. The Group has various non-cancellable lease contracts of office equipment and storage spaces which had a lease term of less than 12 months or were related to leases of low-value assets, and therefore the short-term lease recognition exemption was applied to these contracts. The future lease payments for these non-cancellable lease contracts are EUR 36k within one year (December 31,2019: EUR 72k) and EUR 36k within five years (December 31, 2019: 36k). Future payment obligations As of March 31, 2020, the Group concluded agreements with suppliers, for goods and services to be provided subsequent to March 31, 2020 with a total payment obligation of approximately EUR 778k (December 31, 2019: EUR 802k).

Contingent Liabilities	3 Months Ended
Contingent Liabilities	Mar. 31, 2020
Contingent Liabilities
Contingent Liabilities	13 Contingent Liabilities In May 2016, the Company was informed in writing by the Universitair Medisch Centrum Utrecht ("UMCU") that a claim had been initiated against UMCU regarding a prenatal diagnostic test that the Company conducted at their request which failed to identify a specific mutation present in a patient. On November 8, 2018, the UMCU and Neon Underwriting Limited formally filed a legal claim in the local court in Rostock, Germany against the Company alleging that the Company’s negligence in performing the test resulted in the misdiagnosis of the patient. UMCU is seeking recovery for compensatory damages as a result of the alleged misdiagnosis. By court order of November 8, 2018, the Regional Court of Rostock set the amount in dispute at EUR 880k. The Company intends to rigorously defend its position and considers that it is not probable the legal claim towards the Company will be successful and as a result has not recognized a provision for this claim as of March 31, 2020. In addition, in case a settlement would be required, the Company believes that the corresponding liability will be fully covered by the respective insurance coverage.

Subsequent Event	3 Months Ended
Subsequent Event	Mar. 31, 2020
Subsequent Event
Subsequent Event	14 Subsequent Event Impact of COVID-19 The COVID-19 pandemic, which began in December 2019 in China, has spread across the globe and caused significant disruptions to the society and economy. Different measures, such as quarantines, maintaining social distance, travel restrictions, closure of borders etc. have been implemented by many governments only with the aim to avoid continuous outbreak of the disease. As part of the Company's initiative to help local, national and international authorities in their efforts to the earliest possible diagnosis of COVID-19 and thereby contribute to allowing societies to return to a “new” normal, the Company has commenced testing for COVID-19 in March 2020. Starting from the Mecklenburg-Western Pomerania region of Germany focusing on employees and essential workers in Rostock, the Company further expands the test offering to nursing homes as well as to high school students in Germany. Since May 2020, the Company is offering its tests to the rest of the world in accordance with local rules and regulations. Some of these initiatives are offered free of charge by the Company, while some of them are in collaboration with state government and other companies. To support the expansion of test offering, the Company acquired laboratory facilities and equipment for a total consideration of EUR 1,800k and leased laboratory space in Hamburg, Germany, in April 2020. The lease is charged at a fixed rate and covers a fixed period of five years, with an option to extend. Such lease contract is accounted for under IFRS 16 and accordingly right-of-use assets and lease liabilities of approximately EUR 450k will be recognized. In addition, the Company commenced the production and distribution of a sample collection kit for COVID-19 test, CentoSwab. In addition to its development and testing efforts, as the global COVID-19 pandemic continues to evolve, the Company has continuously been monitoring the situation and has taken a series of measures to protect the employees and safeguard the operations. By the end of May 2020, the Company was able to enable most of the employees to return and work at the office by implementing regular testing. Although the Company is taking a series of measures aiming to minimize the disruptions to the business and operations and the provision of testing for the COVID-19 virus is anticipated to generate additional revenues to the Company, the impact of the pandemic to the global economy, international trade and business activities may also have a negative impact to its operating results. In particular, they could result in increased costs of execution with regards to operational plans. In addition, COVID-19 may disrupt our supply chain, particularly as it relates to the United States (from where a significant proportion of our sequencing products are sourced) as well other countries in which we operate and from where we receive tests, and otherwise adversely affect international trade and business activities. The impact of COVID-19 will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the pandemic, the probability of occurrence of second outbreak, the ultimate impact on financial markets and the global economy etc. Accordingly, the Company is unable to provide a reasonable estimate of the related financial impact at this time. These unaudited interim condensed consolidated financial statements were approved by management on June 15, 2020.

Revenues from contracts with customers (Tables)

3 Months Ended

Mar. 31, 2020

Revenues from contracts with customers

Schedule of geographical information


in EUR k	Three months ended March 31, 2019
	Pharmaceutical	Diagnostics	Total
Rendering of services	3,806	6,585	10,391
Sales of goods	324	—	324
Total Revenues from contracts with external customers	4,130	6,585	10,715

Recognized over time	3,456	6,585	10,041
Recognized at a point in time	674	—	674
Total Revenues from contracts with external customers	4,130	6,585	10,715

Geographical information
Europe	2	1,528	1,530
—Germany*	—	62	62
Middle East	—	3,522	3,522
—Saudi Arabia#	—	1,687	1,687
North America	4,128	677	4,805
—United States#	4,128	408	4,536
Latin America	—	638	638
Asia Pacific	—	220	220
Total Revenues from contracts with external customers	4,130	6,585	10,715

* country of the incorporation of Centogene AG

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended March 31, 2019


in EUR k	Three months ended March 31, 2020
	Pharmaceutical	Diagnostics	Total
Rendering of services	4,274	7,555	11,829
Sales of goods	276	—	276
Total Revenues from contracts with external customers	4,550	7,555	12,105

Recognized over time	4,274	7,555	11,829
Recognized at a point in time	276	—	276
Total Revenues from contracts with external customers	4,550	7,555	12,105

Geographical information
Europe	44	1,617	1,661
—Germany*	19	73	92
—Netherlands**	—	3	3
Middle East	3	4,415	4,418
—Saudi Arabia#	—	3,033	3,033
North America	4,503	620	5,123
—United States#	4,503	471	4,974
Latin America	—	746	746
Asia Pacific	—	157	157
Total Revenues from contracts with external customers	4,550	7,555	12,105

* country of the incorporation of Centogene AG

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended March 31, 2020

Segment information (Tables)

3 Months Ended

Mar. 31, 2020

Segment information

Schedule of segment information and reconciliation of segment adjusted EBITDA to group loss for the period


	Three months ended March 31, 2019
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	4,130	6,585	—	10,715

Adjusted EBITDA	2,944	11	(3,820)	(865)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	7	20	414	441
Additions to intangible assets	768	—	345	1,113

Other segment information
Depreciation and amortization	256	524	617	1,397
Research and development expenses	—	—	1,701	1,701


	Three months ended March 31, 2020
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	4,550	7,555	—	12,105

Adjusted EBITDA	2,608	87	(7,712)	(5,017)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	—	817	587	1,404
Additions to intangible assets	1,002	—	189	1,191

Other segment information
Depreciation and amortization	564	544	976	2,084
Research and development expenses	—	—	2,691	2,691


For the three months ended March 31	2019	2020
Reported segment Adjusted EBITDA	2,955	2,695
Corporate expenses	(3,820)	(7,712)
	(865)	(5,017)
Share-based payment expenses	(2,633)	(1,057)
Depreciation and amortization	(1,397)	(2,084)
Operating loss	(4,895)	(8,158)
Financial costs, net	(212)	(449)
Income tax expenses	(174)	(129)
Loss for the three months ended March 31	(5,281)	(8,736)

Other income and expenses (Tables)

3 Months Ended

Mar. 31, 2020

Other income and expenses

Schedule of other operating income


	For the three months ended March 31
in EUR k	2019	2020
Government grants	967	702
Income from the reversal of provisions	89	—
Others	42	243
Total other operating income	1,098	945

Schedule of other operating expenses


	For the three months ended March 31
in EUR k	2019	2020
Currency losses	2	—
Expected credit loss allowances on trade receivables	340	1,174
Others	—	101
Total other operating expenses	342	1,275

Trade and other receivables and other assets (Tables)

3 Months Ended

Mar. 31, 2020

Trade and other receivables and other assets

Summary of trade and other receivables and other assets


in EUR k	Dec 31, 2019	Mar 31, 2020
Non‑current
Other assets - Rental deposits	1,948	1,948
Other assets – Others	—	150
	1,948	2,098
Current
Trade receivables	12,709	11,089
Contract assets	3,884	3,557
Receivables due from shareholders	2,766	2,766
Other assets	5,846	6,124
	25,205	23,536
Total non-current and current trade and other receivables and other assets	27,153	25,634

Summary of expected credit loss rate on total gross trade receivables and contract assets


in EUR k	Dec 31, 2019		Mar 31, 2020
Not past due	11,102		9,725
Past due 1-30 days	1,113		1,084
Past due 31-90 days	1,708		2,031
Past due more than 90 days	5,005		5,315
Total Gross amount of trade receivables and contract assets	18,928		18,155

Expected credit loss rate
Not past due	0.3	%	0.3	%
Past due 1-30 days	1.0	%	1.3	%
Past due 31-90 days	1.2	%	1.6	%
Past due more than 90 days	45.4	%	64.7	%
Expected credit loss rate on total gross trade receivables and contract assets	12.3	%	19.3	%

Expected credit loss	2,335		3,509

Financial liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Financial liabilities

Schedule of interest-bearing liabilities


in EUR k	Dec 31, 2019	Mar 31, 2020
Non‑current liabilities
Non‑current portion of secured bank loans	968	768
Municipal loans	610	—
Total non‑current loans	1,578	768
Lease liabilities	18,069	18,826
Total non‑current liabilities	19,647	19,594

Current liabilities
Current portion of secured bank loans	802	802
Bank overdrafts	2,636	3,050
Municipal loans	250	—
Total current loans	3,688	3,852
Current portion of lease liabilities	3,635	3,625
Total current liabilities	7,323	7,477
Total non‑current and current liabilities	26,970	27,071

Schedule of outstanding interest-bearing liabilities


					Dec 31, 2019		Mar 31, 2020
		Nominal			Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	interest rate		Maturity	amount	amount	amount	amount
Secured bank loan	EUR	3.95	%	2018‑25	1,770	1,770	1,570	1,570
Municipal loan	EUR	8.25%; plus 1.5% profit-related; 0.75% on losses		2018-23	500	500	—	—
Municipal loan	EUR	8%; plus 1.5% profit-related; 0.75% on losses		2021	360	360	—	—
Bank overdrafts	EUR	4.46	%	2022	476	476	476	476
Bank overdrafts	EUR	3.75	%	Rollover	2,160	2,160	2,094	2,094
Bank overdrafts	EUR	3.59	%	Rollover	—	—	480	480
Lease liabilities	EUR	3.5%*, 5. 4%-8.9%		2017-31	21,704	21,704	22,451	22,451
Total interest‑bearing financial liabilities					26,970	26,970	27,071	27,071

* represents the incremental borrowing rate of the Group at the commencement of the leases

Schedule of trade payables and other liabilities


in EUR k	Dec 31, 2019	Mar 31, 2020
Trade payables	8,554	10,173
Government grants (deferred income)	11,289	11,137
Liability for Virtual Stock Option Program	2,769	2,766
Contract liabilities	3,748	3,523
Others	5,258	6,423
Trade payables and other liabilities	31,618	34,022
Non‑current	9,941	9,773
Current	21,677	24,249

General company information (Details) € / shares in Units, € in Millions, shares in Millions	Nov. 12, 2019	Nov. 07, 2019 $ / shares € / shares	Nov. 07, 2019 EUR (€) € / shares shares
Centogene AG
General Information About Financial Statements [Line Items]
Ownership interest held by company (as a percent)	100.00%
Common shares
General Information About Financial Statements [Line Items]
Number of common shares issued (in shares) \| shares			4
Par value per share \| € / shares		€ 0.12	€ 0.12
Public offering price (in dollars per share) \| (per share)		€ 14.00	€ 12.58
Net offering proceeds \| €			€ 47

Revenues from contracts with customers - Geographical information (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disclosure of geographical areas
Rendering of services	€ 11,829	€ 10,391
Sales of goods	276	324
Total Revenues from contracts with external customers	12,105	10,715
Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,661	1,530
-Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	92	62
-Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	3
Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,418	3,522
-Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,033	1,687
North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	5,123	4,805
-United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,974	4,536
Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	746	638
Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	157	220
Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	11,829	10,041
Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	276	674
Pharmaceutical
Disclosure of geographical areas
Rendering of services	4,274	3,806
Sales of goods	276	324
Total Revenues from contracts with external customers	4,550	4,130
Pharmaceutical \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	44	2
Pharmaceutical \| -Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	19
Pharmaceutical \| -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	0
Pharmaceutical \| Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	3
Pharmaceutical \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,503	4,128
Pharmaceutical \| -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,503	4,128
Pharmaceutical \| Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	0
Pharmaceutical \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,274	3,456
Pharmaceutical \| Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	276	674
Diagnostics
Disclosure of geographical areas
Rendering of services	7,555	6,585
Total Revenues from contracts with external customers	7,555	6,585
Diagnostics \| Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,617	1,528
Diagnostics \| -Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	73	62
Diagnostics \| -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	3
Diagnostics \| Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,415	3,522
Diagnostics \| -Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,033	1,687
Diagnostics \| North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	620	677
Diagnostics \| -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	471	408
Diagnostics \| Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	746	638
Diagnostics \| Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	157	220
Diagnostics \| Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	€ 7,555	€ 6,585

Revenue from contracts with customers - Additional Information (Details) € in Thousands	3 Months Ended
	Mar. 31, 2020 EUR (€) customer	Mar. 31, 2019 EUR (€) customer
Revenue from contracts with customers
Revenue from contracts with customers	€ 12,105	€ 10,715
Provision for expected credit losses on contract assets	€ 1,174	€ 340
Pharmaceutical Partner
Revenue from contracts with customers
Number of customer in group \| customer	1	1
Revenue contributed by one pharmaceutical partner, as a percentage of Group's total revenues	26.40%	27.40%
Revenue from contracts with customers	€ 0	€ 350

Segment information - Information by operating segments (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment information
Total Revenues from contracts with external customers	€ 12,105	€ 10,715
Adjusted EBITDA	(5,017)	(865)
Additions to property, plant and equipment and right-of-use assets	1,404	441
Additions to intangible assets	1,191	1,113
Other segment information
Depreciation and amortization	2,084	1,397
Research and development expenses	2,691	1,701
Pharmaceutical
Segment information
Total Revenues from contracts with external customers	4,550	4,130
Diagnostics
Segment information
Total Revenues from contracts with external customers	7,555	6,585
Operating segment \| Pharmaceutical
Segment information
Total Revenues from contracts with external customers	4,550	4,130
Adjusted EBITDA	2,608	2,944
Additions to property, plant and equipment and right-of-use assets		7
Additions to intangible assets	1,002	768
Other segment information
Depreciation and amortization	564	256
Operating segment \| Diagnostics
Segment information
Total Revenues from contracts with external customers	7,555	6,585
Adjusted EBITDA	87	11
Additions to property, plant and equipment and right-of-use assets	817	20
Other segment information
Depreciation and amortization	544	524
Corporate
Segment information
Adjusted EBITDA	(7,712)	(3,820)
Additions to property, plant and equipment and right-of-use assets	587	414
Additions to intangible assets	189	345
Other segment information
Depreciation and amortization	976	617
Research and development expenses	€ 2,691	€ 1,701

Segment information - Reconciliation of segment Adjusted EBITDA to Group Loss for the Period (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment information
Depreciation and amortization	€ (2,084)	€ (1,397)
Operating loss	(8,158)	(4,895)
Income tax expenses	(129)	(174)
Loss for the period	(8,736)	(5,281)
Operating segment
Segment information
Reportable segment Adjusted EBITDA	2,695	2,955
Reportable segment Adjusted EBITDA after corporate expenses	(5,017)	(865)
Operating loss	(8,158)	(4,895)
Financial costs, net	(449)	(212)
Income tax expenses	(129)	(174)
Loss for the period	(8,736)	(5,281)
Corporate
Segment information
Corporate expenses	(7,712)	(3,820)
Depreciation and amortization	(976)	(617)
Sharebased payment expenses
Segment information
Share-based compensation	(1,057)	(2,633)
Depreciation and amortization
Segment information
Depreciation and amortization	€ (2,084)	€ (1,397)

Segment information - Additional information (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Segment information
Property, plant and equipment	€ 8,709		€ 8,376
Right-of-use assets	24,710		24,932
-United States
Segment information
Property, plant and equipment	276		286
Right-of-use assets	960		€ 1,042
Corporate
Segment information
Share issue related cost	€ 0	€ 109

Other income and expenses - Other operating income (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Other income and expenses
Government grants	€ 702	€ 967
Income from the reversal of provisions		89
Others	243	42
Total other operating income	€ 945	€ 1,098

Other income and expenses - Other operating expenses (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Other income and expenses
Currency losses		€ 2
Expected credit loss allowances on trade receivables	€ 1,174	340
Other	101
Total other operating expenses	€ 1,275	€ 342

Other income and expenses - LPC GmbH (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Other income and expenses
Non-controlling interest	€ (731)	€ (938)
LPC GmbH
Other income and expenses
Proportion of ownership interest in subsidiary	51.00%
Consideration for disposal of subsidiary	€ 213
Consideration to be paid over time	€ 200
Payment due period (in years)	4 years
Non-controlling interest	€ (268)
Profit/(loss) allocated to non-controlling interest	€ (101)

Trade and other receivables and other assets (Details) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Non-current
Other assets-Rental deposits	€ 1,948	€ 1,948
Other assets - Others	150
Trade and other receivables and other assets non-current	2,098	1,948
Current
Trade receivables	11,089	12,709
Contract assets	3,557	3,884
Receivables due from shareholders	2,766	2,766
Other assets	6,124	5,846
Trade and other receivables and other assets current	23,536	25,205
Total non-current and current trade and other receivables and other assets	25,634	27,153
Trade receivables and contract assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 18,155	€ 18,928
Expected credit loss rate	19.30%	12.30%
Expected credit loss	€ 3,509	€ 2,335
Trade receivables and contract assets \| Not past due
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 9,725	€ 11,102
Expected credit loss rate	0.30%	0.30%
Trade receivables and contract assets \| Past due 1-30 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 1,084	€ 1,113
Expected credit loss rate	1.30%	1.00%
Trade receivables and contract assets \| Past due 31-90 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 2,031	€ 1,708
Expected credit loss rate	1.60%	1.20%
Trade receivables and contract assets \| Past due more than 90 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 5,315	€ 5,005
Expected credit loss rate	64.70%	45.40%
Minimum
Current
Receivables payment terms	30 days
Maximum
Current
Receivables payment terms	90 days
Other assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
VAT receivables	€ 1,744	€ 1,311
Prepaid expenses	2,834	3,481
Receivables from grants	743	€ 409
Other assets \| Rostock headquarters building
Credit loss rates in relation to the outstanding trade receivables and contract assets
Cash deposits provided as security for bank loans	1,500
Bank guarantee	3,000
Other assets \| Berlin Offices
Non-current
Other assets-Rental deposits	257
Other assets \| Certain plant and machineries
Non-current
Other assets-Rental deposits	191
Other assets \| LPC GmbH
Credit loss rates in relation to the outstanding trade receivables and contract assets
Consideration receivable for the sale of LPC	213
Consideration receivable for the sale of LPC due after one year	€ 150

Cash and short-term deposits (Details) - EUR (€) € in Thousands	Mar. 31, 2020	Dec. 31, 2019
Secured bank loan
Borrowings
Short term deposits pledged as security	€ 1,500	€ 1,500
Existing Overdraft facility
Borrowings
Short term deposits pledged as security	2,500	2,500
Maximum borrowing capacity	2,500
Second Overdraft facility
Borrowings
Short term deposits pledged as security	500	€ 0
Maximum borrowing capacity	€ 500

Equity - Capital Reserves (Details) € in Thousands	Mar. 31, 2020 EUR (€)
Capital reserve
Share premium included in capital reserve	€ 90,297

Financial liabilities - Interest-bearing loans (Details) - EUR (€) € in Thousands	Mar. 31, 2020	Dec. 31, 2019
Financial liabilities
Total non-current liabilities	€ 19,594	€ 19,647
Total current liabilities	7,477	7,323
Total non-current and current liabilities	27,071	26,970
Total loans
Financial liabilities
Total non-current liabilities	768	1,578
Total current liabilities	3,852	3,688
Secured bank loans
Financial liabilities
Total non-current liabilities	768	968
Total current liabilities	802	802
Short term deposits pledged as security	1,500	1,500
Bank overdrafts
Financial liabilities
Total current liabilities	3,050	2,636
Municipal loans
Financial liabilities
Total non-current liabilities		610
Total current liabilities		250
Lease liabilities
Financial liabilities
Total non-current liabilities	18,826	18,069
Total current liabilities	3,625	3,635
Total non-current and current liabilities	€ 22,451	€ 21,704

Financial liabilities - Conditions and statement of liabilities (Details) - EUR (€) € in Thousands	Mar. 31, 2020	Dec. 31, 2019
Financial liabilities
Nominal amount	€ 27,071	€ 26,970
Carrying amount	27,071	26,970
Bank overdrafts	476	476
Secured bank loans
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	1,500	€ 1,500
Secured bank loans with maturity period 2018 To 25
Financial liabilities
Nominal interest rate (as a percent)		3.95%
Nominal amount	1,570	€ 1,770
Carrying amount	€ 1,570	1,770
Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	3.50%
Nominal amount	€ 22,451	21,704
Carrying amount	€ 22,451	21,704
Municipal loan, 2021, one
Financial liabilities
Nominal interest rate (as a percent)	8.25%
Nominal interest rate profit (as a percent)	1.50%
Nominal interest rate, on losses (as a percent)	0.75%
Nominal amount		500
Carrying amount		500
Municipal loan, 2022
Financial liabilities
Nominal interest rate (as a percent)	8.00%
Nominal interest rate profit (as a percent)	1.50%
Nominal interest rate, on losses (as a percent)	0.75%
Nominal amount		360
Carrying amount		360
Repayment of Municipal Loans
Financial liabilities
Nominal amount		€ 860
Bank overdrafts, one
Financial liabilities
Nominal interest rate (as a percent)		4.46%
Nominal amount	€ 476	€ 476
Carrying amount	476	€ 476
Bank overdrafts, two
Financial liabilities
Nominal interest rate (as a percent)		3.75%
Nominal amount	2,094	€ 2,160
Carrying amount	€ 2,094	2,160
Bank overdrafts, three
Financial liabilities
Nominal interest rate (as a percent)	3.59%
Nominal amount	€ 480
Carrying amount	€ 480
Minimum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	5.00%
Existing Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 2,500	2,500
Second Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 500	€ 0

Financial liabilities - Trade payables and other liabilities (Details) - EUR (€) € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Financial liabilities
Trade payables	€ 10,173		€ 8,554
Government grants (deferred income)	11,137		11,289
Liability for Virtual Stock Option Program	2,766		2,769
Contract liabilities	3,523		3,748
Others	6,423		5,258
Trade payables and other liabilities	34,022		31,618
Non-current	9,773		9,941
Current	24,249		21,677
Grants received for investment in property, plant and equipment	207	€ 0
Personnel related liabilities for vacation and bonuses	2,734		2,264
Liabilities for wage and church tax	€ 356		376
Costs relating to anticipated initial public offering			€ 565

Share-based payments - Equity share option 2017 (Equity settled) (Details) - Equity share option 2017 (Equity settled)	3 Months Ended	12 Months Ended
	Mar. 31, 2020 Options € / shares shares	Dec. 31, 2019
Share-based payments
Number of options granted \| Options	805,308
Number of common shares per option granted \| shares	1
Exercise price of share options \| € / shares	€ 0.12
Lock-up period	180 days
Weighted average remaining contractual life of outstanding share options	9 years 8 months 12 days	10 years

Share-based payments - Equity share option 2019 (Equity settled) (Details) - Equity share option 2019 (Equity settled) - Member of the supervisory board € / shares in Units, € in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020 EUR (€)	Mar. 31, 2019 EUR (€)	Dec. 31, 2019 Options € / shares shares
Share-based payments
Number of options granted \| Options			396,522
Number of common shares per option granted \| shares			1
Exercise price of share options			€ 12.58
Vesting period			3 years
Vesting percentage			33.33%
Weighted average remaining contractual life of outstanding share options			10 years
Weighted average fair value of options outstanding			€ 9.08
Share-based payment expense \| €	€ 1,057	€ 2,633

Commitments (Details) - EUR (€) € in Thousands	3 Months Ended	12 Months Ended
Commitments (Details) - EUR (€) € in Thousands	Mar. 31, 2020	Dec. 31, 2019
Lease commitments
Total payment obligation	€ 778	€ 802
Rostock headquarters building \| Within one year
Lease commitments
Future lease payments to be made	103
Rostock headquarters building \| Within five years
Lease commitments
Future lease payments to be made	1,669
Rostock headquarters building \| Later than 5 years
Lease commitments
Future lease payments to be made	5,324
Office equipment and storage spaces \| Within one year
Lease commitments
Future lease payments to be made	36	72
Office equipment and storage spaces \| Within five years
Lease commitments
Future lease payments to be made	€ 36	€ 36

Contingent Liabilities (Details) € in Thousands	Nov. 08, 2018 EUR (€)
Universitair Medisch Centrum Utrecht
Contingent Liabilities
Dispute amount	€ 880

Subsequent Event (Details) - EUR (€) € in Thousands	1 Months Ended
Subsequent Event (Details) - EUR (€) € in Thousands	Apr. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Subsequent Event
Right-of-use assets		€ 24,710	€ 24,932
Laboratory facilities and equipment \| Major purchases of assets
Subsequent Event
Additions of property plant and equipment	€ 1,800
Lease term (in years)	5 years
Laboratory space \| Significant lease commitment
Subsequent Event
Right-of-use assets	€ 450